跳至主要内容
临床试验/JPRN-UMIN000044316
JPRN-UMIN000044316已完成未知

Immunogenicity and safety of severe acute respiratory syndrome coronavirus 2 vaccination in lung cancer patients receiving immune checkpoint inhibitors: A multicenter observational study in Japan - Immunogenicity and safety of severe acute respiratory syndrome coronavirus 2 vaccination in lung cancer patients receiving immune checkpoint inhibitors: A multicenter observational study in Japan

Shonan Fujisawa Tokushukai Hospital0 个研究点目标入组 70 人开始时间: 2021年5月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients were excluded if they were in the following condition; (1) having already received the vaccine; (2) not wishing to be vaccinated by their own choice or on the recommendation of their physician; and (3) did not provide informed consent.

研究者

相似试验